UBS Group reaffirmed their neutral rating on shares of GlaxoSmithKline (NYSE:GSK) in a report issued on Monday, The Fly reports.
Other analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft upgraded shares of GlaxoSmithKline from a sell rating to a hold rating in a research note on Wednesday, June 23rd. Credit Suisse Group reaffirmed an underperform rating on shares of GlaxoSmithKline in a report on Thursday, June 24th. Baader Bank reaffirmed a buy rating on shares of GlaxoSmithKline in a report on Wednesday, June 2nd. Barclays reaffirmed an underweight rating on shares of GlaxoSmithKline in a report on Monday, July 19th. Finally, Berenberg Bank reaffirmed a buy rating on shares of GlaxoSmithKline in a report on Thursday, August 19th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, GlaxoSmithKline presently has an average rating of Hold and an average price target of $41.00.
Shares of GlaxoSmithKline stock opened at $38.85 on Monday. The firm has a market cap of $104.61 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 2.10 and a beta of 0.70. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.82 and a quick ratio of 0.53. GlaxoSmithKline has a 1 year low of $33.26 and a 1 year high of $42.68. The company has a 50-day moving average of $40.45 and a 200 day moving average of $38.90.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Friday, August 20th will be issued a $0.523 dividend. This represents a $2.09 dividend on an annualized basis and a dividend yield of 5.38%. The ex-dividend date is Thursday, August 19th. GlaxoSmithKline’s payout ratio is 70.13%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GSK. Reilly Financial Advisors LLC raised its stake in GlaxoSmithKline by 131.7% during the 2nd quarter. Reilly Financial Advisors LLC now owns 695 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 395 shares during the period. Evoke Wealth LLC raised its stake in GlaxoSmithKline by 152.6% during the 1st quarter. Evoke Wealth LLC now owns 730 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 441 shares during the period. Evermay Wealth Management LLC bought a new stake in shares of GlaxoSmithKline during the second quarter valued at approximately $26,000. RMR Wealth Builders raised its position in shares of GlaxoSmithKline by 67.1% during the first quarter. RMR Wealth Builders now owns 752 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 302 shares during the last quarter. Finally, SRS Capital Advisors Inc. bought a new stake in shares of GlaxoSmithKline during the second quarter valued at approximately $33,000. Institutional investors own 12.25% of the company’s stock.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
Further Reading: What are the risks of holding treasury bonds?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.